Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
topic
Journal for ImmunoTherapy of Cancer
Journal for ImmunoTherapy of Cancer
27 Defining elite macrophages from tumor-on-a-chip
Yang
Xiang
,
Xiaohan
Feng
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A29;
DOI:
10.1136/jitc-2023-SITC2023.0027
3 External reproducibility of PD-L1 IHC 22C3 pharmDx for colorectal carcinoma specimens at CPS ≥ 1 cutoff
Lining
Hutchinson
,
Armita
Bahadori
,
Megan
Kalpakoff
,
Francisco
Ponce
,
Siena
Tabuena-Frolli
,
Kristopher
Kersch
,
Monika
Polewski
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A3;
DOI:
10.1136/jitc-2023-SITC2023.0003
28 Toward an automated microfluidic platform for monitoring immune response to immunotherapy
Yuqian
Zhang
,
Yohan
Kim
,
Fabrice
Lucien-Matteoni
,
Haidong
Dong
,
Yuguang
Liu
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A30-A31;
DOI:
10.1136/jitc-2023-SITC2023.0028
29 Immune modulation and baseline biomarker correlation with clinical benefit following treatment with COM701+nivolumab+/-BMS-986207 in patients with platinum resistant ovarian cancer
Gady
Cojocaru
,
Zoya
Alteber
,
Assaf
Wool
,
Adi
Shuchami
,
Inbal
Barbiro
,
Roy
Granit
,
Yu
Liang
,
Zurit
Levine
,
Pierre
Ferre
,
Eran
Ophir
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A32-A34;
DOI:
10.1136/jitc-2023-SITC2023.0029
30 Molecular features associated with long survival on tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial
Marlana
Orloff
,
Kevin
Kim
,
Sarah
Stanhope
,
Adel
Benlahrech
,
Emma
Leach
,
Laura
Collins
,
Koustubh
Ranade
,
Brendan
Curti
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A35;
DOI:
10.1136/jitc-2023-SITC2023.0030
31 Development of GMP serum-free cryopreservation solutions for human T cells and mesenchymal stem cells
Zayda
Piedra
,
David
Cruz
,
Jessie
Ni
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A36;
DOI:
10.1136/jitc-2023-SITC2023.0031
32 Identification of predictive biomarkers of clinical response to PD-1 blockade in patients with advanced non-small cell lung cancer
Nikita
Dutta
,
Ella
Eklund
,
Levent
Akyürek
,
Per
Torstensson
,
Volkan
Sayin
,
Anna
Rohlin
,
Andreas
Hallqvist
,
Sukanya
Raghavan
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A37;
DOI:
10.1136/jitc-2023-SITC2023.0032
33 Blood-based tumor mutation burden (bTMB) predicts response to immune checkpoint blockade-based combination therapy (ICBC) in advanced non-small cell lung cancer (NSCLC): a real-world (RW) analysis
Sean
Gordon
,
Bruna
Pellini
,
Reagan
Barnett
,
Jiemin
Liao
,
Katie
Quinn
,
Sara
Wienke
,
Leylah
Drusbosky
,
Nicole
Zhang
,
Martina
Lefterova
,
Lauren
Lawrence
,
Lesli
Kiedrowski
,
Ross
Eppler
,
Justin
Odegaard
,
Han-Yu
Chuang
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A38;
DOI:
10.1136/jitc-2023-SITC2023.0033
34 Association of a novel circulating tumor fraction DNA biomarker of treatment response monitoring and clinical outcomes in a real-world, diverse pan-cancer cohort treated with immunotherapy
John
Guittar
,
Ryan
Gentzler
,
Akash
Mitra
,
Michelle M
Stein
,
Christine
Lo
,
Wei
Zhu
,
Terri
Driessen
,
Justin
Guinney
,
Halla
Nimeiri
,
Rotem
Ben-Shachar
,
Jyoti
Patel
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A39;
DOI:
10.1136/jitc-2023-SITC2023.0034
4 Combinations of immune checkpoint inhibitors with fractionated radiotherapy or DNA damage response agents leads to improved anti-tumour responses and modulates the tumour immune microenvironment
Charlotte
Bell
,
Theoni
Katopodi
,
Yin Xin
Ho
,
Pablo
Binder
,
Tobias
Bunday
,
Emily
Wright
,
Amy
Cantrell
,
Nick
Moore
,
Stewart
Brown
,
Paul
Farrington
,
Shannon
Sharman
,
Lyndsey
Hanson
,
Lorraine
Mooney
,
Jane
Kendrew
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A4;
DOI:
10.1136/jitc-2023-SITC2023.0004
Pages
« first
‹ previous
…
215
216
217
218
219
220
221
222
223
…
next ›
last »
Special collections
COVID-19
(45)
Editor's choice
JITC
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Basic Tumor Immunology
(560)
Case Reports
(191)
Clinical Trials Monitor
(17)
Clinical/Translational Cancer Immunotherapy
(983)
Commentary/Editorials
(153)
Computational I-O
(4)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(56)
Guidelines and Consensus Statements
(53)
Imaging and Immunotherapy
(9)
Immune Cell Therapies and Immune Cell Engineering
(242)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(437)
Liquid Biopsies
(10)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(151)
Reviews
(245)
The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC)
(1)
Open access
(5026)
Press releases
(2)
